Cancer, fatigue and the return of patients to work—a prospective cohort study
Introduction
Cancer-related fatigue has been described as “the commonest and most debilitating symptom in patients with cancer” [1]. From an individual's point of view, not being able to return to work following an illness, frequently results in financial losses, social isolation and a reduction in self-esteem 2, 3. Conversely, returning to work can improve the quality of life of many cancer patients. Patients often see returning to work as proof of a complete recovery. Treating clinicians, as well as occupational physicians, may contribute to a successful return to work, and can thus enhance the quality of life of cancer patients [4]. The economic impact is considerable: 75% of patients and 40% of those who care for these patients change their employment status because of cancer-related fatigue [1]. From a societal point of view, it is therefore important to reduce avoidable work incapacity resulting in such economic loss [5].
Cancer is a collective name for a heterogeneous group of diagnoses whose treatment is far from uniform. There is some evidence that the consequences of the illness and its treatment, or cancer-related symptoms that are experienced by the patients, can affect the likelihood of resumption of work by cancer patients. For example, the relatively rapid return to work of patients with testis carcinoma is explained by the relative absence of cancer-related symptoms [6]. Although, concentrating on differences at the level of diagnosis bears the risk of generalisation: e.g. not all patients with testis carcinoma experience few problems following work resumption.
Cancer-related symptoms are in general independent of the cancer site and treatment. Fatigue is one of the best-known and best-researched symptoms. Other equally relevant cancer-related symptoms are depression, sleep problems, physical complaints, cognitive dysfunction and psychological distress 7, 8, 9. Cancer-related fatigue can have psychological and physical causes and is as such associated with other cancer-related symptoms: e.g. sleep problems, depression and physical complaints [1].
Cancer-related symptoms are not only highly prevalent in cancer patients, irrespective of the cancer site, but they are also likely to have an impact in a wide variety of work settings and may thus hinder the resumption of work. In addition to cancer-related symptoms, the impact of clinical, work-related and subject-related variables [6] on the resumption of work needs to be considered, including diagnosis and treatment, physical workload [10], work stress, age, gender and work hours [6].
The aim of the present study was to examine the relationship between fatigue and other cancer-related symptoms and the return to work in cancer patients, taking into account the impact of clinical-, work- and subject-related factors (Fig. 1). The impact of the symptoms will be considered in a cohort of cancer survivors starting from 6 months following their first day of sick leave. The research question is: do the symptom scores at 6 months after the first day of sick leave predict the time taken to return to work and the rate of return to work at 12 months of follow-up?
Section snippets
Subjects
In this prospective-cohort study, patients who had a primary diagnosis of cancer were consecutively included in the study. Recruitment occurred in three hospitals in The Netherlands: the Academic Medical Centre and the Onze Lieve Vrouwe Gasthuis, both in Amsterdam, and in the hospital De Heel in Zaandam. The following departments were also included in the study: Gynaecology, Haematology, Oncology, Surgery, Radiotherapy, and Urology. The attending physician obtained the patient's informed
Sample characteristics
235 of the 264 patients who were eligible and were approached, completed the first questionnaire (response rate of 89%). Of the 29 patients who declined participation in the study; 12 were not interested, 13 were too ill, 2 participated in a concurrent study and 2 declined for other reasons. Hospital directions prohibited us to collect additional information on the patients who did not participate. The follow-up questionnaire at 18 months following the first day of sick leave was completed by
Discussion
In this study, 64% of the cancer patients had returned to work at 18 months following their first day of sick leave. Fatigue levels at 6 months after the start of sick leave predicted the return to work at 18 months following the first day of sick leave. This was independent of the diagnosis and treatment, but not of other cancer-related symptoms. Age and physical workload were also independently related to the return to work. The other potential predictive factors sleep problems, cognitive
Acknowledgments
This study was supported by a grant from the Dutch Cancer Society (AMC 97-1385). We are grateful to all of the patients for their participation in this study. In addition, we would like to thank the medical staff involved at the Academic Medical Center, the Onze Lieve Vrouwe Gasthuis and at hospital De Heel for their indispensable contribution to this study and Dr M.M. Verberk for his constructive comments.
References (17)
Cancer-related symptoms
Semin. Radiat. Oncol.
(2000)- et al.
The Multidimensional Fatigue Inventory, psychometric qualities of an instrument to assess fatigue
J. Psychometric Res.
(1995) - et al.
The Pittsburgh Sleep Quality Index (PSQI)a new instrument for psychiatric practice and research
Psychiatric Res.
(1989) Fatigue in cancer; like pain, this is a symptom that physicians can and should manage
Br. Med. J.
(2001)Work and Illness: The Cancer Patient
(1989)Societal Perspective on the Cost of Illness
(1998)- et al.
Work problems after breast canceran exploratory qualitative study
Psychooncology
(1999) - et al.
Vocational rehabilitation; everybody gains if injured workers are helped back into work
Br. Med. J.
(2001)
Cited by (246)
Associations between fatigue and cellular metabolism in breast cancer patients: A longitudinal study
2022, PsychoneuroendocrinologyCitation Excerpt :Approximately 50 % of patients with breast cancer experience moderate to severe fatigue during treatment (de Jong et al., 2004), and over 25 % continue to experience severe fatigue following primary cancer treatment (Abrahams et al., 2016). The experience of cancer-related fatigue (CRF) is associated with symptoms of psychological distress and often contributes to financial stress as well: fatigue is one of the most cited reasons for taking unpaid medical leave, going on disability, and in general not returning to the workforce (Spelten et al., 2003). An estimated 21.7 million cancer survivors will be living in the United States in 2029 (Cancercontrol.cancer.gov/ocs/statistics/statistics, 2019); over 7 million of them will suffer from CRF.
Current challenges in cancer care in Brussels-capital region: A qualitative study
2021, Bulletin du CancerEffects of mindfulness-based interventions on fatigue in cancer survivors: A systematic review and meta-analysis of randomized controlled trials
2021, Critical Reviews in Oncology/HematologyCitation Excerpt :Fatigue profoundly interferes with survivors’ activities and mood (Wang et al., 2014; Curt et al., 2000) and is often associated with other disruptive symptoms (e.g., sleep disturbance, pain, anxiety, depressive symptoms) (Kuhnt et al., 2009; Minton et al., 2012), attentional disturbance (Minton and Stone, 2012; Askren et al., 2014), and impaired health-related quality of life (Curt et al., 2000; Ferreira et al., 2008). Fatigue is also associated with increased healthcare utilization (Goldstein et al., 2012), significant disability (Goldstein et al., 2012; Blaney et al., 2010; Piper et al., 2008), and financial burden resulting from disability (Curt et al., 2000; Spelten et al., 2003; Yabroff et al., 2004; Buckwalter et al., 2007). One treatment for fatigue with rapid growth in popularity in the past two decades is mindfulness-based intervention (MBI).
Prevalence, severity, and risk factors of cancer-related fatigue among working cancer survivors: a systematic review and meta-analysis
2024, Journal of Cancer Survivorship